Dysferlin deficiency enhances monocyte phagocytosis

A model for the inflammatory onset of limb-girdle muscular dystrophy 2B

Kanneboyina Nagaraju, Rashmi Rawat, Edina Veszelovszky, Rachana Thapliyal, Akanchha Kesari, Susan Sparks, Nina Raben, Paul Plotz, Eric P. Hoffman

Research output: Contribution to journalArticle

Abstract

Dysferlin deficiency causes limb-girdle muscular dystrophy type 2B (LGMD2B; proximal weakness) and Miyoshi myopathy (distal weakness). Muscle inflammation is often present in dysferlin deficiency, and patients are frequently misdiagnosed as having polymyositis. Because monocytes normally express dysferlin, we hypothesized that monocyte/macrophage dysfunction in dysferlin-deficient patients might contribute to disease onset and progression. We therefore examined phagocytic activity, in the presence and absence of cytokines, in freshly isolated peripheral blood monocytes from LGMD2B patients and in the SJL dysferlin-deficient mouse model. Dysferlin-deficient monocytes showed increased phagocytic activity compared with control cells. siRNA-mediated inhibition of dysferlin expression in the J774 macrophage cell line resulted in significantly enhanced phagocytosis, both at baseline and in response to tumor necrosis factor-α. Immunohistochemical analysis revealed positive staining for several mononuclear cell activation markers in LGMD2B human muscle and SJL mouse muscle. SJL muscle showed strong up-regulation of endocytic proteins CIMPR, clathrin, and adaptin-α, and LGMD2B muscle exhibited decreased expression of decay accelerating factor, which was not dysferlin-specific. We further showed that expression levels of small Rho family GTPases RhoA, Rac1, and Cdc 42 were increased in dysferlin-deficient murine immune cells compared with control cells. Therefore, we hypothesize that mild myofiber damage in dysferlin-deficient muscle stimulates an inflammatory cascade that may initiate, exacerbate, and possibly perpetuate the underlying myofiber-specific dystrophic process.

Original languageEnglish (US)
Pages (from-to)774-785
Number of pages12
JournalAmerican Journal of Pathology
Volume172
Issue number3
DOIs
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

Limb-Girdle Muscular Dystrophies
Phagocytosis
Monocytes
Muscles
Macrophages
CD55 Antigens
Polymyositis
rho GTP-Binding Proteins
Clathrin
Monomeric GTP-Binding Proteins
Diagnostic Errors
Small Interfering RNA
Disease Progression
Up-Regulation
Tumor Necrosis Factor-alpha
Type 2B Limb-girdle muscular dystrophy
Staining and Labeling
Cytokines
Inflammation
Cell Line

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Nagaraju, K., Rawat, R., Veszelovszky, E., Thapliyal, R., Kesari, A., Sparks, S., ... Hoffman, E. P. (2008). Dysferlin deficiency enhances monocyte phagocytosis: A model for the inflammatory onset of limb-girdle muscular dystrophy 2B. American Journal of Pathology, 172(3), 774-785. https://doi.org/10.2353/ajpath.2008.070327

Dysferlin deficiency enhances monocyte phagocytosis : A model for the inflammatory onset of limb-girdle muscular dystrophy 2B. / Nagaraju, Kanneboyina; Rawat, Rashmi; Veszelovszky, Edina; Thapliyal, Rachana; Kesari, Akanchha; Sparks, Susan; Raben, Nina; Plotz, Paul; Hoffman, Eric P.

In: American Journal of Pathology, Vol. 172, No. 3, 03.2008, p. 774-785.

Research output: Contribution to journalArticle

Nagaraju, K, Rawat, R, Veszelovszky, E, Thapliyal, R, Kesari, A, Sparks, S, Raben, N, Plotz, P & Hoffman, EP 2008, 'Dysferlin deficiency enhances monocyte phagocytosis: A model for the inflammatory onset of limb-girdle muscular dystrophy 2B', American Journal of Pathology, vol. 172, no. 3, pp. 774-785. https://doi.org/10.2353/ajpath.2008.070327
Nagaraju, Kanneboyina ; Rawat, Rashmi ; Veszelovszky, Edina ; Thapliyal, Rachana ; Kesari, Akanchha ; Sparks, Susan ; Raben, Nina ; Plotz, Paul ; Hoffman, Eric P. / Dysferlin deficiency enhances monocyte phagocytosis : A model for the inflammatory onset of limb-girdle muscular dystrophy 2B. In: American Journal of Pathology. 2008 ; Vol. 172, No. 3. pp. 774-785.
@article{55bc0291178c4b6e9e30fbfd1375be79,
title = "Dysferlin deficiency enhances monocyte phagocytosis: A model for the inflammatory onset of limb-girdle muscular dystrophy 2B",
abstract = "Dysferlin deficiency causes limb-girdle muscular dystrophy type 2B (LGMD2B; proximal weakness) and Miyoshi myopathy (distal weakness). Muscle inflammation is often present in dysferlin deficiency, and patients are frequently misdiagnosed as having polymyositis. Because monocytes normally express dysferlin, we hypothesized that monocyte/macrophage dysfunction in dysferlin-deficient patients might contribute to disease onset and progression. We therefore examined phagocytic activity, in the presence and absence of cytokines, in freshly isolated peripheral blood monocytes from LGMD2B patients and in the SJL dysferlin-deficient mouse model. Dysferlin-deficient monocytes showed increased phagocytic activity compared with control cells. siRNA-mediated inhibition of dysferlin expression in the J774 macrophage cell line resulted in significantly enhanced phagocytosis, both at baseline and in response to tumor necrosis factor-α. Immunohistochemical analysis revealed positive staining for several mononuclear cell activation markers in LGMD2B human muscle and SJL mouse muscle. SJL muscle showed strong up-regulation of endocytic proteins CIMPR, clathrin, and adaptin-α, and LGMD2B muscle exhibited decreased expression of decay accelerating factor, which was not dysferlin-specific. We further showed that expression levels of small Rho family GTPases RhoA, Rac1, and Cdc 42 were increased in dysferlin-deficient murine immune cells compared with control cells. Therefore, we hypothesize that mild myofiber damage in dysferlin-deficient muscle stimulates an inflammatory cascade that may initiate, exacerbate, and possibly perpetuate the underlying myofiber-specific dystrophic process.",
author = "Kanneboyina Nagaraju and Rashmi Rawat and Edina Veszelovszky and Rachana Thapliyal and Akanchha Kesari and Susan Sparks and Nina Raben and Paul Plotz and Hoffman, {Eric P.}",
year = "2008",
month = "3",
doi = "10.2353/ajpath.2008.070327",
language = "English (US)",
volume = "172",
pages = "774--785",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Dysferlin deficiency enhances monocyte phagocytosis

T2 - A model for the inflammatory onset of limb-girdle muscular dystrophy 2B

AU - Nagaraju, Kanneboyina

AU - Rawat, Rashmi

AU - Veszelovszky, Edina

AU - Thapliyal, Rachana

AU - Kesari, Akanchha

AU - Sparks, Susan

AU - Raben, Nina

AU - Plotz, Paul

AU - Hoffman, Eric P.

PY - 2008/3

Y1 - 2008/3

N2 - Dysferlin deficiency causes limb-girdle muscular dystrophy type 2B (LGMD2B; proximal weakness) and Miyoshi myopathy (distal weakness). Muscle inflammation is often present in dysferlin deficiency, and patients are frequently misdiagnosed as having polymyositis. Because monocytes normally express dysferlin, we hypothesized that monocyte/macrophage dysfunction in dysferlin-deficient patients might contribute to disease onset and progression. We therefore examined phagocytic activity, in the presence and absence of cytokines, in freshly isolated peripheral blood monocytes from LGMD2B patients and in the SJL dysferlin-deficient mouse model. Dysferlin-deficient monocytes showed increased phagocytic activity compared with control cells. siRNA-mediated inhibition of dysferlin expression in the J774 macrophage cell line resulted in significantly enhanced phagocytosis, both at baseline and in response to tumor necrosis factor-α. Immunohistochemical analysis revealed positive staining for several mononuclear cell activation markers in LGMD2B human muscle and SJL mouse muscle. SJL muscle showed strong up-regulation of endocytic proteins CIMPR, clathrin, and adaptin-α, and LGMD2B muscle exhibited decreased expression of decay accelerating factor, which was not dysferlin-specific. We further showed that expression levels of small Rho family GTPases RhoA, Rac1, and Cdc 42 were increased in dysferlin-deficient murine immune cells compared with control cells. Therefore, we hypothesize that mild myofiber damage in dysferlin-deficient muscle stimulates an inflammatory cascade that may initiate, exacerbate, and possibly perpetuate the underlying myofiber-specific dystrophic process.

AB - Dysferlin deficiency causes limb-girdle muscular dystrophy type 2B (LGMD2B; proximal weakness) and Miyoshi myopathy (distal weakness). Muscle inflammation is often present in dysferlin deficiency, and patients are frequently misdiagnosed as having polymyositis. Because monocytes normally express dysferlin, we hypothesized that monocyte/macrophage dysfunction in dysferlin-deficient patients might contribute to disease onset and progression. We therefore examined phagocytic activity, in the presence and absence of cytokines, in freshly isolated peripheral blood monocytes from LGMD2B patients and in the SJL dysferlin-deficient mouse model. Dysferlin-deficient monocytes showed increased phagocytic activity compared with control cells. siRNA-mediated inhibition of dysferlin expression in the J774 macrophage cell line resulted in significantly enhanced phagocytosis, both at baseline and in response to tumor necrosis factor-α. Immunohistochemical analysis revealed positive staining for several mononuclear cell activation markers in LGMD2B human muscle and SJL mouse muscle. SJL muscle showed strong up-regulation of endocytic proteins CIMPR, clathrin, and adaptin-α, and LGMD2B muscle exhibited decreased expression of decay accelerating factor, which was not dysferlin-specific. We further showed that expression levels of small Rho family GTPases RhoA, Rac1, and Cdc 42 were increased in dysferlin-deficient murine immune cells compared with control cells. Therefore, we hypothesize that mild myofiber damage in dysferlin-deficient muscle stimulates an inflammatory cascade that may initiate, exacerbate, and possibly perpetuate the underlying myofiber-specific dystrophic process.

UR - http://www.scopus.com/inward/record.url?scp=40449085244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449085244&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2008.070327

DO - 10.2353/ajpath.2008.070327

M3 - Article

VL - 172

SP - 774

EP - 785

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -